Document is current
Any future updates will be listed below
-
Authors
Martínez-Riaño, Ana https://orcid.org/0000-0001-6880-3107
Cuesta, Raquel
Salinas, Dayanna
Soria, Nekane https://orcid.org/0009-0002-4205-6857
Alexandru, Raluca https://orcid.org/0009-0002-1903-5636
Molero-Glez, Paula
Ruiz-Guillamon, David
Azpilikueta, Arantza
Luri-Rey, Carlos https://orcid.org/0000-0001-6476-0998
Lopez-Janeiro, Álvaro
de Andrea, Carlos E https://orcid.org/0000-0002-7628-8050
Aymerich, María S https://orcid.org/0000-0001-9750-1538
Berraondo, Pedro https://orcid.org/0000-0001-7410-1865
Teijeira, Álvaro
Melero, Ignacio https://orcid.org/0000-0002-1360-348X
-
Funding
Funding for this research was provided by:
EC | Horizon Europe | Excellent Science | HORIZON EUROPE Marie Sklodowska-Curie Actions (MSCA-2023-PF 101149181)
MEC | Agencia Estatal de Investigación (PID2023-147515OB-I00)
MEC | Agencia Estatal de Investigación (PID2024-156660OA-100)
MEC | Agencia Estatal de Investigación (RYC2023-042880-I)
'la Caixa' Foundation (LCF/PR/HR21/00083)
Fundació la Marató de TV3 (488/C/2019)
Fundación Fero (BBASELGAFERO2022-01)
MEC | Instituto de Salud Carlos III (PI21/01547[CEDA])
Mark Foundation For Cancer Research (ASPIRE Award)
- License Information
-
More Information
Article History
Received: 4 January 2026
Revised: 27 July 2026
Accepted: 29 July 2026
First Online: 25 August 2026
Disclosure and competing interests statement
: IM reports grants and personal fees from Genmab during the conduct of the study, as well as grants and personal fees from Bristol Myers Squibb, Roche, AstraZeneca, Pharmamar and personal fees from F-Star, Numab, Pieris, Boehringer Ingelheim, Gossamer, Alligator, Hotspot, Biolinerx, Bioncotech, Dompe, Highlight Therapeutics, Bright Peaks and Boston Therapeutics outside the submitted work.
